JP7191030B2 - Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合 - Google Patents

Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合 Download PDF

Info

Publication number
JP7191030B2
JP7191030B2 JP2019548419A JP2019548419A JP7191030B2 JP 7191030 B2 JP7191030 B2 JP 7191030B2 JP 2019548419 A JP2019548419 A JP 2019548419A JP 2019548419 A JP2019548419 A JP 2019548419A JP 7191030 B2 JP7191030 B2 JP 7191030B2
Authority
JP
Japan
Prior art keywords
cells
fusion protein
soluble
domain
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019548419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508691A (ja
JP2020508691A5 (enExample
Inventor
ウォーレン ディー． マーカス，
ロバート ニューマン，
バイ リウ，
リジン ヨウ，
リン コン，
ピーター ロード，
ヒン シー． ウォン，
Original Assignee
アルター・バイオサイエンス・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルター・バイオサイエンス・コーポレーション filed Critical アルター・バイオサイエンス・コーポレーション
Publication of JP2020508691A publication Critical patent/JP2020508691A/ja
Publication of JP2020508691A5 publication Critical patent/JP2020508691A5/ja
Priority to JP2022194613A priority Critical patent/JP2023027174A/ja
Application granted granted Critical
Publication of JP7191030B2 publication Critical patent/JP7191030B2/ja
Priority to JP2024082540A priority patent/JP7720950B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4234—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
JP2019548419A 2017-03-06 2018-03-06 Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合 Active JP7191030B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022194613A JP2023027174A (ja) 2017-03-06 2022-12-06 Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合
JP2024082540A JP7720950B2 (ja) 2017-03-06 2024-05-21 Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762467623P 2017-03-06 2017-03-06
US62/467,623 2017-03-06
PCT/US2018/021220 WO2018165208A1 (en) 2017-03-06 2018-03-06 Il-15-based fusions to il-12 and il-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022194613A Division JP2023027174A (ja) 2017-03-06 2022-12-06 Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合

Publications (3)

Publication Number Publication Date
JP2020508691A JP2020508691A (ja) 2020-03-26
JP2020508691A5 JP2020508691A5 (enExample) 2021-04-15
JP7191030B2 true JP7191030B2 (ja) 2022-12-16

Family

ID=63448011

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019548419A Active JP7191030B2 (ja) 2017-03-06 2018-03-06 Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合
JP2022194613A Pending JP2023027174A (ja) 2017-03-06 2022-12-06 Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合
JP2024082540A Active JP7720950B2 (ja) 2017-03-06 2024-05-21 Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022194613A Pending JP2023027174A (ja) 2017-03-06 2022-12-06 Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合
JP2024082540A Active JP7720950B2 (ja) 2017-03-06 2024-05-21 Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合

Country Status (8)

Country Link
US (8) US11129883B2 (enExample)
EP (1) EP3592778A4 (enExample)
JP (3) JP7191030B2 (enExample)
KR (4) KR102625293B1 (enExample)
CN (2) CN110785435B (enExample)
AU (1) AU2018231170B2 (enExample)
CA (2) CA3055318C (enExample)
WO (1) WO2018165208A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2388266B1 (en) * 2007-05-11 2014-04-23 Altor BioScience Corporation Fusion molecules and IL-15 variants
KR102625293B1 (ko) * 2017-03-06 2024-01-15 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
CN107384859A (zh) * 2017-09-05 2017-11-24 四川新生命干细胞科技股份有限公司 一种高纯度nk细胞的分离培养方法
JP7795181B2 (ja) 2017-09-06 2026-01-07 イェール ユニバーシティー インターロイキン－１８バリアントとその利用法
CN119876019A (zh) * 2018-03-01 2025-04-25 格雷戈里奥马拉尼翁医院生物医学研究基金会 获得源自胸腺组织的调节性t细胞的方法及所述细胞作为细胞免疫疗法在免疫系统失调中的用途
WO2020023713A1 (en) * 2018-07-26 2020-01-30 Nantbio, Inc. Tri-cytokine txm compositions and methods
CN112996805A (zh) * 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
CA3109139A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2020047333A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
WO2020051363A1 (en) * 2018-09-07 2020-03-12 Nantbio, Inc. Targeted il-12 treatments and methods to stimulate hank and nk92mi cells
AU2020294797B2 (en) * 2019-06-21 2025-12-18 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
CA3117134A1 (en) * 2019-07-08 2021-01-14 Nantkwest, Inc. Ciml nk cells and methods therefor
CN113166726A (zh) 2019-07-08 2021-07-23 南克维斯特公司 单核细胞源性nk细胞
US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells
US20210008107A1 (en) * 2019-07-08 2021-01-14 Nantkwest, Inc. CIML NK cells and Methods Therefor
WO2021044439A1 (en) * 2019-09-08 2021-03-11 Immunoadaptive Cell Therapy Pvt Ltd. Inducible cytokine signals & methods for immunotherapy
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
EP4037700A2 (en) * 2019-10-03 2022-08-10 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
WO2021097227A1 (en) * 2019-11-14 2021-05-20 Altor Bioscience, Llc Il-15 fusion protein enhanced adoptive cell therapeutics
KR102400884B1 (ko) * 2019-11-15 2022-05-23 주식회사 제넥신 변형된 인터루킨-7 및 인터루킨-2를 포함하는 융합단백질 및 이의 용도
WO2021163299A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
CN116670163A (zh) 2020-02-11 2023-08-29 Hcw生物科技公司 治疗年龄相关疾病和炎性疾病的方法
AU2021262794B2 (en) 2020-04-29 2026-06-18 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
GB202102049D0 (en) * 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
US20240228964A9 (en) * 2021-03-03 2024-07-11 Immunitybio, Inc. Highly Potent M-CENK Cells And Methods
EP4351320A1 (en) 2021-06-09 2024-04-17 ImmunityBio, Inc. Methods and systems for producing a protein of interest in a plant
CN114853899B (zh) * 2021-11-02 2024-05-28 北京华奥玄德生物医药科技有限公司 一种il-12和il-18变体的融合蛋白及其制备方法和用途
US12594323B2 (en) 2022-04-13 2026-04-07 Immunitybio, Inc. Methods of reducing neuroinflammation
US20240150422A1 (en) * 2022-07-18 2024-05-09 Onko-Innate Pty Ltd Il-12 fc fusion proteins and uses thereof
US20260048099A1 (en) * 2022-08-16 2026-02-19 The United States Of America, As Represented By The Secretary, Deparment Of Health And Human Service Synergistic interactions for improved cancer treatment
US20240327484A1 (en) * 2023-03-31 2024-10-03 Immunitybio, Inc. Il-12/il-18 superkines
JP2026524303A (ja) * 2023-06-14 2026-07-22 フューズ バイオセラピューティクス インコーポレイテッド 単一及び複数サイトカイン融合タンパク質、並びにその使用
WO2025068413A1 (en) * 2023-09-28 2025-04-03 Prokarium Limited Interleukin 18 variants
WO2025184052A1 (en) * 2024-02-26 2025-09-04 Allegheny Singer Research Institute Interleukin 2 and interleukin 12 fusion proteins and methods of using
US20260027155A1 (en) 2024-07-23 2026-01-29 Immunitybio, Inc. Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products
WO2026039841A1 (en) * 2024-08-16 2026-02-19 Board Of Regents, The University Of Texas System Tetra protein targeted killer engagers (tetrakes) in bladder cancer treatment
WO2026112610A1 (en) * 2024-11-25 2026-05-28 Immunitybio, Inc. Nk-92 cells with cytokine induced memory-like cytotoxicity and derivatives thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514057A (ja) 2002-12-31 2006-04-27 シェーリング　コーポレイション 哺乳類のサイトカイン；関連試薬の使用
US20100303811A1 (en) 2008-06-16 2010-12-02 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity.
JP2011045375A (ja) 2003-07-21 2011-03-10 Transgene Sa 新規多機能性サイトカイン
US20140242025A1 (en) 2010-09-21 2014-08-28 Altor Bioscience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
AU5098393A (en) 1992-08-14 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant toxin with increased half-life
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5534592A (en) 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
KR101131297B1 (ko) 2003-11-10 2012-03-30 알토 바이오사이언스 코포레이션 가용성 티씨알 분자 및 이용 방법
EP2388266B1 (en) 2007-05-11 2014-04-23 Altor BioScience Corporation Fusion molecules and IL-15 variants
CN101687933B (zh) * 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
PL3351261T3 (pl) * 2011-10-11 2021-12-06 Universität Zürich Lek złożony zawierający IL-12 i środek do blokowania cząsteczek hamujących komórki T w terapii nowotworów
CA2953816C (en) 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
MX2019004681A (es) * 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
KR102625293B1 (ko) 2017-03-06 2024-01-15 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
JP2020533971A (ja) 2017-08-28 2020-11-26 アルター・バイオサイエンス・コーポレーション Ｉｌ−１５をベースとするｉｌ−７及びｉｌ−２１への融合物
US11168138B2 (en) 2018-03-26 2021-11-09 Altor Bioscience, Llc Anti-PDL1, IL-15 and TGF-beta receptor combination molecules

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514057A (ja) 2002-12-31 2006-04-27 シェーリング　コーポレイション 哺乳類のサイトカイン；関連試薬の使用
JP2011045375A (ja) 2003-07-21 2011-03-10 Transgene Sa 新規多機能性サイトカイン
US20100303811A1 (en) 2008-06-16 2010-12-02 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity.
US20140242025A1 (en) 2010-09-21 2014-08-28 Altor Bioscience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Res, 2013 May 3, vol. 73, no. 10, pp. 3075-3086
J Innate Immun, 2015 Apr 30, vol. 7, no. 6, pp. 563-571
Oncoimmunology, 2013 Apr, vol. 2, no. 4, article no. e23811 (pp. 1-3)

Also Published As

Publication number Publication date
US11129883B2 (en) 2021-09-28
CA3216726C (en) 2025-08-05
WO2018165208A1 (en) 2018-09-13
KR20240173369A (ko) 2024-12-11
KR20250150164A (ko) 2025-10-17
JP2020508691A (ja) 2020-03-26
US20220062399A1 (en) 2022-03-03
US20250152686A1 (en) 2025-05-15
CN110785435A (zh) 2020-02-11
KR102739572B1 (ko) 2024-12-10
US12233116B2 (en) 2025-02-25
KR102625293B1 (ko) 2024-01-15
US20240252609A1 (en) 2024-08-01
US11872272B2 (en) 2024-01-16
AU2018231170A1 (en) 2019-09-19
CN117986384A (zh) 2024-05-07
US11612645B2 (en) 2023-03-28
CN110785435B (zh) 2024-01-23
EP3592778A1 (en) 2020-01-15
CA3055318A1 (en) 2018-09-13
JP7720950B2 (ja) 2025-08-08
KR20190126115A (ko) 2019-11-08
JP2024109747A (ja) 2024-08-14
US20190046623A1 (en) 2019-02-14
AU2018231170B2 (en) 2020-07-16
US20240100138A1 (en) 2024-03-28
US11975059B2 (en) 2024-05-07
CA3216726A1 (en) 2018-09-13
US11571470B2 (en) 2023-02-07
EP3592778A4 (en) 2021-01-13
US20250018020A1 (en) 2025-01-16
CA3055318C (en) 2025-11-25
JP2023027174A (ja) 2023-03-01
KR20230170821A (ko) 2023-12-19
US20220387570A1 (en) 2022-12-08
US20230248813A1 (en) 2023-08-10
KR102867975B1 (ko) 2025-10-14

Similar Documents

Publication Publication Date Title
JP7720950B2 (ja) Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合
US12410224B2 (en) IL-15-based fusions to IL-7 and IL-21
US11318201B2 (en) Multimeric IL-15-based molecules
HK40014316A (en) Multimeric il-15-based molecules
HK40014316B (en) Multimeric il-15-based molecules

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210305

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221206

R150 Certificate of patent or registration of utility model

Ref document number: 7191030

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250